nice_new_london_office_internal_2_8

NICE reject Clovis Oncology’s ovarian cancer drug Rubraca

pharmafile | August 6, 2019 | News story | Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma 

Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib).

On 6 August, NICE issued draft guidance that does not recommend Rubraca for maintenance treatment of relapsed ovarian, fallopian tube or peritoneal cancer that has responded to platinum-based chemotherapy.

While data from clinical trials shows the drug extends the length of time a person’s cancer progresses compared with placebo (median of 10.8 months in the rucaparib group compared with 5.4 months in the placebo group), it is not known how much longer people live due to immature trial data.

Advertisement

However, the cost effectiveness estimates are also higher than the amounts the NHS considers an acceptable use of resources. Furthermore, rucaparib does not meet the criteria for inclusion in the cancer drugs fund.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

Five Facts about NHS and primary care

1 Primary care is the front door to the NHS, but it extends well beyond …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content